Lilly gearing up for 'substantial expansion' of diabetes med manufacturing by 2025

An Eli Lilly executive recently referred to the demand for its diabetes drugs as “unprecedented.” The company may have to come up with another level descriptor if Mounjaro—which was approved seven months ago for Type 2 diabetes—adds an indication to treat obesity.